Compare EPRT & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | SYRE |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | 112 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 8.0B |
| IPO Year | 2018 | 2015 |
| Metric | EPRT | SYRE |
|---|---|---|
| Price | $26.90 | $87.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $36.79 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | N/A |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | $43.34 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $26.47 | $15.49 |
| 52 Week High | $34.73 | $110.18 |
| Indicator | EPRT | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.93 |
| Support Level | N/A | $82.83 |
| Resistance Level | N/A | $92.10 |
| Average True Range (ATR) | 0.00 | 3.30 |
| MACD | 0.00 | 0.48 |
| Stochastic Oscillator | 0.00 | 65.46 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.